FrancophonIA/ELRC3.0 huggingface dataset:
English: Blood thyroid stimulating hormone increased Gamma-glutamyltransferase increased
Slovenian: Preiskave zvišana alkalna fosfazata v krvi zvišan tiroideo stimulirajoči hormon v krvi zvišana gama-glutamiltransferaza
English: Rarely, gastric scarring causing stricture or pyloric stenosis (alone or in combination) may lead to partial or complete bowel obstruction 2-5 weeks after ingestion.
Slovenian: V redkih primerih v 2-5 tednih po zaužitju lahko pride do delne ali popolne obstrukcije črevesja zaradi brazgotinjenja v želodcu, ki povzroči strikturo ali pilorično stenozo (samostojno ali v kombinaciji).
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Norgine B.V.
Slovenian: IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Norgine B.V.
English: Store below 25°C.
Slovenian: Shranjujte pri temperaturi do 25 C.
English: PHARMACEUTICAL FORM AND CONTENTS 56 capsules METHOD AND ROUTE(S) OF ADMINISTRATION Oral use.
Slovenian: FARMACEVTSKA OBLIKA IN VSEBINA 56 kapsul POSTOPEK IN POT(I) UPORABE ZDRAVILA peroralna uporaba Pred uporabo preberite priloženo navodilo!
English: Concomitant use of iron with methyldopa should be avoided as oral iron may antagonise the hypotensive effect of methyldopa.
Slovenian: Treba se je izogibati sočasni uporabi železa in metildope, ker peroralno železo lahko nevtralizira hipotenzivni učinek metildope.
English: Proportion of subjects that achieved normalised Hb at Week
Slovenian: Delež preiskovance v, ki je v 12. tednu dosegel normalno vrednost Hb
English: Tabulated list of adverse reactions Table 1 presents all adverse reactions occurring during clinical studies to date with Feraccru.
Slovenian: V preglednici 1 so navedeni vsi neželeni učinki, ki so se pojavili v kliničnih študijah z zdravilom Feraccru do zdaj.
English: Peak transferrin saturation (TSAT) and total serum iron values were reached 1.5 to 3 hours after oral administration of Feraccru.
Slovenian: Največja nasičenost transferina (TSAT) in skupna raven železa v serumu sta bili doseženi po 1,5 ure do 3 ur po peroralni uporabi zdravila Feraccru.
English: Administration of iron preparations with such compounds should be separated by at least 2 hours.
Slovenian: Zdravila z železom in tovrstne spojine je treba jemati z vsaj dveurnim razmikom.
English: This medicinal product also contains Allura Red AC (E129) and Sunset Yellow FCF (E110): these may cause allergic reactions.
Slovenian: To zdravilo vsebuje tudi barvili alurno rdeče AC (E129) in sončno rumenoFCF (E110), ki lahko povzročita alergijske reakcije.
English: Skin and subcutaneous tissue disorders
Slovenian: Bolezni kože in podkožja akne eritem
English: Maximum maltol and maltol glucuronide concentrations were reached approximately 1 hour after oral administration of Feraccru.
Slovenian: Največje koncentracije maltola in maltolovegaglukuronida so bile dosežene približno 1 uro po peroralni uporabi zdravila Feraccru.
English: Capsule contents: Lactose monohydrate Sodium laurilsulfate Magnesium stearate Colloidal anhydrous silica
Slovenian: Vsebina kapsule: laktoza monohidrat natrijev lavrilsulfat magnezijev stearat koloidni brezvodni silicijev dioksid krospovidon (vrsta A)
English: As a precautionary measure, it is preferable to avoid the use of Feraccru during pregnancy.
Slovenian: Iz previdnostnih razlogov se je med nosečnostjo uporabi zdravila Feraccru bolje izogibati.
English: SN: {number}
Slovenian: < PC: {številka} SN: {številka NN: {številka}
English: Feraccru contains iron (as ferric maltol).
Slovenian: Zdravilo Feraccru vsebuje železo (v obliki železovega maltola).
English: 83 % of the patients with CD had a CDAI-score <150 and 17 % a CDAI-score >150-220.
Slovenian: 69 % bolnikov z UK je imelo rezultat SCCAI ≤ 2, 31 % pa je imelo rezultat SCCAI 3. 83 % bolnikov s CB je imelo rezultat CDAI< 150, 17 % pa je imelo rezultat CDAI> 150-220.
English: • Nausea (feeling sick)
Slovenian: • slabost (siljenje na bruhanje),
English: Feraccru capsules contain lactose, Sunset Yellow FCF (E110) and Allura Red AC (E129).
Slovenian: Kapsule zdravila Feraccru vsebujejo laktozo, barvilo sončno rumeno FCF (E110) in barvilo alurno rdeče AC (E129).
English: NAME OF THE MEDICINAL PRODUCT Feraccru 30 mg hard capsules Iron (as ferric maltol) STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains 30 mg iron (as ferric maltol).
Slovenian: IME ZDRAVILA Feraccru 30 mg trde kapsule železo (v obliki železovega maltola) NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena kapsula vsebuje 30 mg železa (v obliki železovega maltola).
English: UNIQUE IDENTIFIER - 2D BARCODE <2D barcode carrying the unique identifier included.>
Slovenian: <Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.>
English: Maximum maltol and maltol glucuronide concentrations were reached 1 to 1.5 hours after oral administration of Feraccru.
Slovenian: Največje koncentracije maltola in maltolovegaglukuronida so bile dosežene po 1 uri do 1,5 ure po peroralni uporabi zdravila Feraccru.
English: No reproductive and developmental toxicity or carcinogenicity studies have been conducted with ferric maltol.
Slovenian: Z železovim maltolom niso izvedli študij o vplivu na razmnoževanje in razvoj ali študij kancerogenosti.
English: No clinical data on the need to adjust the dosage in patients with impaired hepatic or renal function are available (see section 4.4).
Slovenian: Kliničnih podatkov, da bi bilo treba pri bolnikih z jetrno ali ledvično okvaro odmerek prilagoditi, ni (glejte poglavje 4.4) Način uporabe peroralna uporaba
English: LIST OF EXCIPIENTS Contains lactose, Sunset Yellow (E110) and Allura Red (E129).
Slovenian: SEZNAM POMOŽNIH SNOVI Vsebuje laktozo, barvilo sončno rumeno (E110) in barvilo alurno rdeče (E129).
English: These medicinal products should be given at least 2 hours apart from Feraccru.
Slovenian: Ta zdravila in zdravilo Feraccru je treba jemati vsaj z dveurnim razmikom.
English: The median time since last dose of OFP was 22 months in the experimental group and 17 months in the placebo arm. 52 % of the patients in AEGIS 1 and 33 % in AEGIS 2 had a disease flare in the previous 6 months.
Slovenian: 52 % bolnikov v študiji AEGIS 1 in 33 % bolnikov v študiji AEGIS 2 je doživelo izbruh bolezni v prejšnjih 6 mesecih.
English: What Feraccru contains The active substance is 30 mg of iron as ferric maltol.
Slovenian: Kaj vsebuje zdravilo Feraccru Zdravilna učinkovina je 30 mg železa v obliki železovega maltola.
English: Iron deficiency or iron deficiency anaemia (IDA) diagnosis should be made based on blood tests; it is important to investigate the cause of the iron deficiency and to exclude underlying causes of anaemia other than iron deficiency.
Slovenian: Pomembno je, da se s preiskavami ugotovi vzrok za pomanjkanje železa in izključijo drugi vzroki anemije.
English: Nervous system disorders
Slovenian: Bolezni živčevja glavobol
English: SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 11.
Slovenian: ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI 11.
English: Serum iron levels measured at about 4 hours after ingestion is the best laboratory measure of severity.
Slovenian: Najboljše laboratorijsko merilo resnosti je serumska koncentracija železa, izmerjena 4 ure po zaužitju.
English: How to take Feraccru
Slovenian: Kako jemati zdravilo Feraccru
English: Outer packaging: carton of 1 bottle
Slovenian: PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI Zunanja ovojnina: škatla z eno plastenko
English: As a precautionary measure, it is preferable to avoid the use of Feraccru during breast-feeding.
Slovenian: Iz previdnostnih razlogov se je med dojenjem uporabi zdravila Feraccru bolje izogibati.
English: Musculoskeletal and connective tissue disorders
Slovenian: Bolezni mišično-skeletnega sistema in vezivnega tkiva togost sklepov bolečina v udu
English: Proportion of subjects that achieved ≥1 g/dL change in Hb at Week
Slovenian: Delež preiskovancev, ki je v 12. tednu dosegel spremembo vrednosti Hb za ≥ 1 g/dl (%)
English: 4.5 Interaction with other medicinal products and other forms of interaction No drug interaction studies have been performed with Feraccru.
Slovenian: Študij medsebojnega delovanja z zdravilom Feraccru niso izvedli.
English: Administration of iron preparations and tetracyclines should be separated by 2 to 3 hours.
Slovenian: Zdravila z železom in tetracikline je treba jemati z dve- do triurnim razmikom.
English: Taking too much Feraccru can make the person feel sick or be sick and cause bellyache and diarrhoea.
Slovenian: Če ste vzeli večji odmerek zdravila Feraccru, kot bi smeli Če vzamete preveč zdravila Feraccru, vam je lahko slabo ali bruhate, vas boli trebuh ali imate drisko.
English: Fertility was unaffected following maltol treatment in animal studies.
Slovenian: Zdravljenje z maltolom v študijah na živalih ni vplivalo na plodnost.
English: MARKETING AUTHORISATION HOLDER Norgine B.V.
Slovenian: IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM Norgine B.V.
English: Non-clinical studies revealed no special hazard for humans based on repeated dose toxicity and local tolerance studies conducted with ferric maltol.
Slovenian: Predklinični podatki na osnovi študij toksičnosti pri ponavljajočih odmerkih in študij lokalnega prenašanja, opravljene z železovim maltolom, ne kažejo posebnega tveganja za človeka
English: Absorption of both iron and antibiotic may be reduced if oral iron is given with tetracycline.
Slovenian: Če se peroralno železo daje s tetraciklinom, se lahko zmanjša absorpcija obeh, železa in antibiotika.
English: Proportion of subjects that achieved ≥2 g/dL change in Hb at Week
Slovenian: Delež preiskovancev, ki je v 12. tednu dosegel spremembo vrednosti Hb za ≥ 2 g/dl (%)
English: Other medicines and Feraccru
Slovenian: Shranjevanje zdravila Feraccru
English: You should leave at least 2 hours between taking Feraccru and taking:
Slovenian: Med jemanjem zdravila Feraccru in naslednjimi zdravili boste morali narediti vsaj dveurni razmik:
English: Deposition of iron in the reticulo-endothelial system, liver and spleen was recorded in dogs administered 250 mg/kg/day ferric maltol.
Slovenian: Pri psih, ki so prejemali 250 mg železovega maltola/kg/dan, so zabeležili odlaganje železa v retikuloendotelijskem sistemu, jetrih in vranici.
English: There are no data from the use of Feraccru in pregnant women.
Slovenian: Nosečnost Podatkov o uporabi zdravila Feraccru pri nosečnicah ni. Železov maltol ni sistemsko razpoložljiv.
English: Do not take Feraccru: - If you are allergic to ferric maltol or any of the other ingredients of this medicine (listed in section 6).
Slovenian: Ne jemljite zdravila Feraccru: - če ste alergični na železov maltol ali katero koli sestavino tega zdravila (navedeno v poglavju 6), - če imate bolezen, ki povzroča preobremenitev z železom, ali motnjo izrabe železa v vašem telesu, - če ste prejeli več transfuzij krvi.
English: • Diarrhoea
Slovenian: • driska,
English: Package leaflet: Information for the patient Feraccru 30 mg hard capsules Iron (as ferric maltol)
Slovenian: Feraccru 30 mg trde kapsule železo (v obliki železovega maltola)
English: Faeces discolouration was observed in patients treated with ferric maltol in clinical trials.
Slovenian: V kliničnih študijah je bila pri bolnikih, zdravljenih z železovim maltolom, opažena sprememba barve blata.
English: There are no data on the effect of ferric maltol on human fertility.
Slovenian: Podatkov o učinku izpostavljenosti železovemu maltolu na plodnost pri človeku ni. Železov maltol ni sistemsko razpoložljiv.
English: General disorders and administration site conditions
Slovenian: Splošne težave in spremembe na mestu aplikacije žeja
English: Haemosiderin was observed in Kupffer cells of dogs administered 250 mg/kg/day maltol.
Slovenian: Pri psih, ki so prejemali 250 mg maltola/kg/dan, so v Kupfferjevih celicah opazili hemosiderin.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 30 mg iron (as ferric maltol).
Slovenian: Ena kapsula vsebuje 30 mg železa (v obliki železovega maltola).
English: Ferric maltol
Slovenian: Železov maltol
English: Norgine B.V. medinfo.benelux@norgine.com
Slovenian: medinfo.benelux@norgine.com
English: Call your doctor or hospital straightaway if you or another person has taken too much Feraccru.
Slovenian: Če ste vi ali kdo drug vzeli večji odmerek zdravila Feraccru, kot bi smeli, takoj pokličite zdravnika ali bolnišnico.
English: Hb change (g/dL) from Baseline* at Week 8
Slovenian: Sprememba vrednosti Hg (g/dL) glede na izhodišče* v 8. tednu Povprečje (SE)
English: • Stomach pain
Slovenian: • bolečine v želodcu,
English: Hb change (g/dL) from Baseline* at Week 4
Slovenian: Sprememba vrednosti Hg (g/dL) glede na izhodišče* v 4. tednu Povprečje (SE)
English: Abdominal pain (including upper abdomen) Flatulence
Slovenian: Bolezni prebavil bolečine v trebuhu (vključno z zgornjim delom trebuha) flatulenca zaprtje nelagodje/napihnjenostv trebuhu driska sprememba barve blata slabost bakterijsko preraščanje v tankem črevesju bruhanje
English: Mean (SE)
Slovenian: Ferracru(N = 64
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
Slovenian: PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI Primarna ovojnina: nalepka na plastenki
English: Marketing Authorisation Holder Norgine B.V.
Slovenian: Norgine B.V.
English: Method of administration
Slovenian: NAČIN IZDAJANJA ZDRAVILA
English: EXPIRY DATE
Slovenian: DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
English: What measures are being taken to ensure the safe and effective use of Sialanar?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Sialanar?
English: The starting dose depends on the patient's body weight.
Slovenian: Začetni odmerek je odvisen od bolnikove telesne mase.
English: The full EPAR for Sialanar can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Sialanar je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Sialanar.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Sialanar.
English: Sialanar is available as a solution to be taken by mouth three times a day, one hour before or two hours after meals.
Slovenian: Zdravilo Sialanar je na voljo v obliki raztopine, ki se jemlje peroralno trikrat na dan, eno uro pred obrokom ali dve uri po njem.
English: What benefits of Sialanar have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Sialanar izkazalo v študijah?
English: What are the risks associated with Sialanar?
Slovenian: Kakšna tveganja so povezana z zdravilom Sialanar?
English: It must also not be used in patients who are pregnant or are taking potassium chloride tablets or capsules or medicines which have anticholinergic effect.
Slovenian: Prav tako se ne sme uporabljati pri nosečnicah ali bolnikih, ki jemljejo kalijev klorid v obliki tablet ali kapsul ali zdravila, ki imajo antiholinergični učinek.
English: These receptors trigger the production of saliva when activated by nerves from the brain.
Slovenian: Ti receptorji sprožijo nastajanje sline, ko jih aktivirajo živci v možganih.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore concluded that benefits of Sialanar outweigh its risks and recommended that it be granted marketing authorisation in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zato zaključil, da so koristi zdravila Sialanar večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: Other information about Sialanar
Slovenian: Druge informacije o zdravilu Sialanar
English: The dose is then adjusted according to how the patient responds to the medicine and its side effects.
Slovenian: Odmerek se nato prilagodi glede na bolnikov odziv na zdravilo in njegove neželene učinke.
English: What is Sialanar and what is it used for?
Slovenian: Kaj je zdravilo Sialanar in za kaj se uporablja?
English: Glycopyrronium bromide is well established in the EU as a treatment for drooling, and published studies show that it is effective in treating severe drooling in children and adolescents with nervous system conditions which can affect their quality of life.
Slovenian: Glikopironijev bromid je v EU dobro uveljavljen za zdravljenje slinjenja in objavljene študije dokazujejo, da je učinkovit pri zdravljenju hudega slinjenja pri otrocih in mladostnikih z boleznimi živčevja, ki lahko vplivajo na kakovost njihovega življenja.
English: With regard to its risks, the side effects that occur with glycopyrronium bromide can be managed by adequately monitoring patients and adjusting the dose.
Slovenian: Glede na tveganja se neželeni učinki, ki se pojavijo pri uporabi glikopironijevega bromida, lahko obvladujejo z ustreznim spremljanjem bolnikov in prilagajanjem odmerka.
English: This study focused on the average final drooling scores after 8 weeks of treatment, which were 1.9 in patients on glycopyrronium bromide and 6.3 in patients on placebo.
Slovenian: Ta študija se je osredotočila na povprečno končno oceno po lestvici slinjenja po osmih tednih zdravljenja, ki je bila 1,9 pri bolnikih, ki so prejemali glikopironijev bromid, in 6,3 pri bolnikih, ki so prejemali placebo.
English: Why is Sialanar approved?
Slovenian: Zakaj je bilo zdravilo Sialanar odobreno?
English: By blocking the receptors, the medicine is expected to help reduce the amount of saliva produced by the glands and so reduce drooling.
Slovenian: Zdravilo naj bi z zaviranjem teh receptorjev pomagalo zmanjšati količino sline, ki jo proizvajajo žleze slinavke, in tako zmanjšalo slinjenje.
English: It is not intended to provide practical advice on how to use Sialanar.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: The most common side effects with Sialanar (which may affect more than 1 in 10 people) are irritability, flushing, blocked nose, reduced secretions in the airways, dry mouth, constipation, diarrhoea, vomiting and inability to completely empty the bladder (urinary retention).
Slovenian: Najpogostejši neželeni učinki zdravila Sialanar (ki lahko prizadenejo več kot 1 osebo od 10) so razdražljivost, vročinski oblivi, zamašen nos, manjše izločanje sluzi v dihalnih poteh, suha usta, zaprtje, driska, bruhanje in nezmožnost popolne izpraznitve mehurja (zastajanje urina).
English: For more information about treatment with Sialanar, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Sialanar preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Two published studies showed that glycopyrronium bromide was effective at reducing drooling in children and adolescents with nervous system conditions, using a standard rating scale known as mTDS (where a score of 1 means no drooling and a score of 9 means profuse drooling).
Slovenian: Dve objavljeni študiji sta pokazali, da je glikopironijev bromid učinkovit pri zmanjševanju slinjenja pri otrocih in mladostnikih z boleznimi živčevja, pri čemer so uporabili standardno lestvico, imenovano mTDS (kjer ocena 1 pomeni nič slinjenja in ocena 9 pomeni močno slinjenje).
English: The active substance in Sialanar, glycopyrronium bromide, blocks receptors in the salivary glands known as muscarinic receptors.
Slovenian: Zdravilna učinkovina v zdravilu Sialanar, glikopironijev bromid, zavira receptorje v žlezah slinavkah, znane kot muskarinski receptorji.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sialanar have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Sialanar upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: Sialanar glycopyrronium bromide
Slovenian: Sialanar glikopironijev bromid
English: The second study involved 27 children and adolescents with severe drooling who took either glycopyrronium bromide or placebo for 8 weeks and then had their treatment switched for another 8 weeks.
Slovenian: V drugo študijo je bilo vključenih 27 otrok in mladostnikov s hudim slinjenjem, ki so osem tednov jemali ali glikopironijev bromid ali placebo in nato še osem tednov drugo obliko zdravljenja.
English: Sialanar is a medicine for treating severe drooling of saliva in children and adolescents (aged 3 years and above) with conditions affecting the nervous system, such as cerebral palsy, epilepsy and neurodegenerative diseases.
Slovenian: Sialanar je zdravilo za zdravljenje hudega slinjenja pri otrocih in mladostnikih (starejših od treh let) z boleznimi, ki prizadenejo živčevje, kot so cerebralna paraliza, epilepsija in nevrodegenerativne bolezni.
English: In one of the studies in 38 children and adolescents with severe drooling, around 74% of those taking glycopyrronium bromide after 8 weeks had their scores reduced by 3 points or more compared with 18% of those taking placebo (a dummy treatment).
Slovenian: V eni študiji z 38 otroki in mladostniki s hudim slinjenjem se je pri 74 % bolnikov, ki so jemali glikopironijev bromid, po osmih tednih stanje izboljšalo za 3 točke ali več v primerjavi z 18 % bolnikov, ki so prejemali placebo (zdravilo brez zdravilne učinkovine).
English: For practical information about using Sialanar, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Sialanar naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: It contains the active substance glycopyrronium bromide.
Slovenian: Vsebuje zdravilno učinkovino glikopironijev bromid.
English: To help prescribers and carers use the medicine as safely as possible, the company that markets Sialanar will provide them with educational material containing information on how to use the medicine properly and manage its side effects.
Slovenian: Družba, ki trži zdravilo Sialanar, bo zdravnikom, ki predpisujejo zdravilo, in skrbnikom v pomoč za čim varnejšo uporabo zdravila zagotovila izobraževalno gradivo, ki bo vsebovalo informacije o pravilni uporabi zdravila in obvladovanju njegovih neželenih učinkov.
English: How is Sialanar used?
Slovenian: Kako se zdravilo Sialanar uporablja?
English: Sialanar should be prescribed by a doctor with experience in treating children with nervous system conditions and it can only be obtained with a prescription.
Slovenian: Zdravilo Sialanar mora predpisati zdravnik, ki ima izkušnje z zdravljenjem otrok z boleznimi živčevja.
English: Sialanar must not be used in patients with glaucoma (an eye condition), urinary retention, severe kidney impairment or a history of certain intestinal conditions or myasthenia gravis (a condition affecting muscles).
Slovenian: Zdravilo Sialanar se ne sme uporabljati pri bolnikih z glavkomom (očesno boleznijo), zastajanjem urina, hudimi obolenji ledvic ali preteklimi boleznimi prebavil ali miastenijo gravis (bolezen, ki prizadene mišice).
English: For the full list of restrictions with Sialanar, see the package leaflet.
Slovenian: Za celoten seznam omejitev pri uporabi zdravila Sialanar glejte navodilo za uporabo.
English: For the full list of all side effects reported with Sialanar, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Sialanar, glejte navodilo za uporabo.
English: How does Sialanar work?
Slovenian: Kako zdravilo Sialanar deluje?
English: Elderly patients (≥65 years)
Slovenian: Starejši bolniki (≥ 65 let)
English: Otherwise, wait for your next dose.
Slovenian: V nasprotnem primeru počakajte na naslednji odmerek.
English: Tell your doctor as soon as possible.
Slovenian: O tem čim prej obvestite zdravnika.
English: Development of resistance
Slovenian: Razvoj odpornosti